ETF model portfolios designed for real investor needs. Discover →
iShares Genomics Immunology and Healthcare ETF
IDNA performance and flow charts
Performance
Flows
Historic performance and flows
Data as of April 17, 2026| 1M | 3M | YTD | 1Y | 3Y | 5Y | |
|---|---|---|---|---|---|---|
| Perf. | +5.80% | +8.83% | +18.94% | +62.75% | +31.20% | -28.13% |
| Flows | +$5M | +$11M | +$11M | +$4M | -$15M | +$10M |
Characteristics
The iShares Genomics Immunology and Healthcare ETF is built to track the NYSE FactSet Global Genomics and Immuno Biopharma Index NTR - USD. This ETF provides physical exposure - by owning its shares you earn the return of the securities composing the index (as the ETF holds them directly). This share class generates a stream of income by distributing dividends.
| Management strategy | Passive |
| Strategy | Long Only |
| Provider | iShares |
| N° of holdings | 51 |
| Replication method | Direct (Physical) |
| Asset class | Equity |
| Dividend policy | Distributing |
Trailing 12m distribution yield | Join for free |
| Inception date | June 11, 2019 |
| ESG | No |
More data and info about IDNA on Trackinsight
Exposure
Data as of February 28, 2026Diversification
Total weight of top 15 holdings out of 51
Top 15 Holdings
Sectors
Countries
Similar ETFs
Trading data
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Volatility | +25.25% | +23.99% | +24.08% | +27.97% |
Max drawdown | -10.60% | -10.60% | -30.61% | -68.19% |
Max drawdown duration | 46d | 46d | 279d | 1671d |
Time to recover | 18d | 18d | 123d | N/A |
Replication quality
Data as of March 31, 2026Create an account to view replication metrics
1 year cumulative return difference | |
|---|---|
| Best | Join for free |
| Worst | Join for free |
| daily return difference | |
|---|---|
| Average | Join for free |
| Worst | Join for free |
What type of ETF is IDNA?
IDNA is a Passive ETF that provides exposure to Equity assets. It is managed by iShares.
What index does IDNA track?
IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index NTR - USD, aiming to replicate its performance through full replication.
What does IDNA invest in?
This ETF provides exposure to Global Equities. It is part of the segment: BioTech & Genomics.
What is the expense ratio of IDNA?
The total expense ratio (TER) of IDNA is 0.47%, representing the annual fee charged by the fund manager.
When was IDNA launched?
IDNA was launched on June 11, 2019, marking its entry into the ETF market.
Who is the issuer of IDNA?
IDNA is issued by iShares.
What is the AUM of IDNA?
As of April 17, 2026, IDNA manages $166.61 M, reflecting the total assets held in the fund.
How has IDNA performed recently?
As of April 17, 2026, IDNA delivered a return of 5.8% over the past month (1M performance), 8.83% over the past three months (3M), and 18.94% year-to-date (YTD).
What are the recent fund flows for IDNA?
As of April 17, 2026, IDNA has seen net flows of +$5M in the past month (1M flow) and +$11M year-to-date (YTD).
Does IDNA pay dividends?
As of April 17, 2026, IDNA has a trailing 12-month distribution yield of 0.99%.
How many holdings are in IDNA
As of February 28, 2026, IDNA holds 51 securities in its portfolio. This level of diversification can influence the fund’s risk profile and exposure to individual assets.
How diversified is IDNA?
As of February 28, 2026, IDNA holds 51 securities, with 62.77% of its assets concentrated in its top 15 holdings.
What are the top holdings of IDNA?
As of February 28, 2026, IDNA holds a portfolio of 51 underlyings, with its largest positions including MODERNA INC, ARCELLX and IPSEN PROMESSES. These top holdings play a significant role in shaping the fund’s performance and exposure.
What countries or regions does IDNA invest in?
As of February 28, 2026, IDNA has its largest geographic exposures in USA and France.
What sectors or themes does IDNA focus on?
As of February 28, 2026, IDNA is primarily exposed to Health Care.
Advantages of ETFs over Mutual Funds1/6
Lower Costs
In this guide, we'll explore the advantages of ETFs over mutual funds, giving you valuable insights into why ETFs have gained significant popularity among investors like yourself.
Leveraged ETFs: Unlocking the Potential for Amplified Returns1/6
Understanding Leveraged ETFs
Explore leveraged ETFs: potential for amplified returns & risks. 5 ETFs to consider across equities, commodities & fixed income.
What is a Leveraged ETF?1/6
Introducing Leveraged and Inverse ETFs
In this guide, we'll dive into the world of leveraged ETFs, exploring their definition, mechanics, potential risks, and rewards.
Recent educational content
Asset TV
The ETF Show - Investors Run to Cash Alternatives as Markets Remain Volatile
Jason England, Portfolio Manager and Fixed Income Strategist from Simplify joined The ETF Show to discuss investor allocations to fixed income as markets continue on their rollercoaster ride.
ETF Trends
ETF Industry KPIs March 30, 2026
The ETF Industry saw 33 New Launches, 1 Ticker Change and 9 closures last week.
Asset TV
The ETF Show - Private Market ETFs Have Huge Demand, But Liquidity Concerns
Jerry Prior, COO and CIO of Managed Futures at Mount Lucas Management spoke with The ETF Show about the growing demand for private market access inside the ETF wrapper, and the concerns over illiquidity.
Asset TV
The ETF Show - Option Income ETF Strategies
Will Rhind, Founder & CEO of GraniteShares joins The ETF Show to discuss option income ETF strategies and their growing popularity amongst investors.
Browse all educational columns
Active Trader Report: Use of Leveraged & Inverse ETFs Way Up
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
